[Cernilton in the treatment of prostatic adenoma and chronic prostatitis].

E. G. Aslamazov,N. Akhvlediani,A. Vinarov,I. G. Aliaev
Urologiia
Abstract:The efficacy of the drug cernilton was studied in patients with prostatic adenoma (PA) and chronic bacterial prostatitis (CBP). One group and two subgroups of patients were studied: 31 men with PA received cernilton for 3 months (group 1); 32 patients with CBP received antibacterial treatment (for 8 months) and cernilton for 3 months (group IIa); 30 CBP patients received standard antibiotic treatment for 2 months maximally (group IIb). All the patients were examined before the treatment and 3 months later. According to IPSS, patients of group 1 showed a significant (p < 0.001) regress of low urinary tract symptoms and improvement of quality of life. PSA in the serum lowered by 21.2%. Qmax significantly increased (p < 0.001), Vprost and Vres diminished. According to the scale NIH-CPSI, relief of pain, dysuria was greater, quality of life improved more in patients of group IIa than in group IIb (p < 0.05). The same trend was in the values Qmax, Vres and Vprost. Thus, it is evident that cernilton is effective in monotherapy of PA and combined treatment of CBP.
What problem does this paper attempt to address?